Canaccord Genuity Assumes Coverage on Optimer Pharmaceuticals (OPTR) at Buy; FDA Panel Expected to Weigh Favorably on Fidaxo NDA
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 50
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 50
Join SI Premium – FREE
Canaccord Genuity assumes coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Buy. PT $16.
Canaccord analyst says, "Going into an upcoming FDA advisory committee meeting on Tuesday, we maintain our rating on OPTR given our view of high likelihood of support for the company’s lead drug, fidaxomicin, for treatment of C. diff. infection. Briefing documents expected for release on Friday could support this claim, thus setting the stage for marketing approval by the May 30 PDUFA date." (Coverage has been transitioned to George Farmer)
"Initially to be positioned in a “high-risk” treatment market and in vancomycin
failures, we model for a slow ramp to peak fidaxomicin sales of $250M by
2016. More rapid adoption will depend largely on physician experience and
accelerated acceptance by hospital formularies."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $11.94 yesterday.
Canaccord analyst says, "Going into an upcoming FDA advisory committee meeting on Tuesday, we maintain our rating on OPTR given our view of high likelihood of support for the company’s lead drug, fidaxomicin, for treatment of C. diff. infection. Briefing documents expected for release on Friday could support this claim, thus setting the stage for marketing approval by the May 30 PDUFA date." (Coverage has been transitioned to George Farmer)
"Initially to be positioned in a “high-risk” treatment market and in vancomycin
failures, we model for a slow ramp to peak fidaxomicin sales of $250M by
2016. More rapid adoption will depend largely on physician experience and
accelerated acceptance by hospital formularies."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $11.94 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- B.Riley Starts Okeanis Eco Tankers Corp (ECO) at Buy, 'solid competitive advantage'
- William Blair Starts On Holding AG (ONON) at Outperform, 'e see a path to three-year revenue growth above 25%'
- Benchmark Starts Penn National Gaming (PENN) at Hold
Create E-mail Alert Related Categories
FDA, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
